Vanda Pharmaceuticals Inc. reported a net loss of $220.5M in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to a $274.8M net loss. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Vanda Pharmaceuticals Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
VNDA Net Income by Fiscal Year
Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | TTM | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$274.8M | -$220.5Mn/m | -$18.9M-853.3% | $2.5M-60.0% | $6.3M-81.1% | $33.2M+42.1% | $23.3M-79.8% | $115.6M+358.4% | $25.2Mn/m | -$15.6Mn/m | -$18.0Mn/m | -$39.9M-297.5% | $20.2Mn/m | -$21.1Mn/m | -$28.6Mn/m | -$9.8M |
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
VNDA Net Income by Quarter
Figures are in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Vanda Pharmaceuticals Inc. financials
Frequently Asked Questions
Vanda Pharmaceuticals Inc. reported a net loss of $220.5M in fiscal year 2025.
Vanda Pharmaceuticals Inc. (VNDA) reported a $18.9M net loss in fiscal year 2024 and a $220.5M net loss in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Vanda Pharmaceuticals Inc. (VNDA) reported a $274.8M net loss over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
Across the 15 fiscal years this page covers, Vanda Pharmaceuticals Inc. (VNDA) net income went from -$9.8M in fiscal year 2011 to -$220.5M in fiscal year 2025.
Vanda Pharmaceuticals Inc. (VNDA) reported -$22.6M in net income in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Vanda Pharmaceuticals Inc. (VNDA) reported on that line in every period on record.